Metal-support interaction in supported Pt single-atom catalyst promotes lattice oxygen activation to achieve complete oxidation of acetone at low concentrations

Tian Tang(University of Alberta), Honghong Yi(University of Science and Technology Beijing), Yiming Ma(University of Science and Technology Beijing), Long Sun(University of Science and Technology Beijing), Shunzheng Zhao(University of Science and Technology Beijing), Xiaolong Tang(Guizhou University), Yunpeng Liu(Shenyang Institute of Automation), Ronghui Zhu(University of Science and Technology Beijing)
Journal of Hazardous Materials
September 15, 2024
10.1016/j.jhazmat.2024.135839
Cited by 16

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
|The Lancet Oncology|2015|412